What is the role of vitamin D in autism?

John J Cannell, William B Grant, John J Cannell, William B Grant

Abstract

A growing body of literature suggests that higher serum 25-hydroxyvitamin D [25(OH)D] concentrations, either in utero or in early life, may reduce the risk of autism. For example, an ecological study in the companion paper inversely correlated solar UV-B doses in the United States with prevalence of autism among those aged 6-17 y. That study proposed that vitamin D deficiency during pregnancy could account for this finding, although the findings are also consistent with childhood vitamin D deficiency contributing to the condition. Also, in a recent study, children with autism had lower serum 25(OH)D concentrations than did control subjects (19 vs. 33 ng/ml), despite parents of each group reporting the same amount of sun exposure. The same study found highly significant inverse correlations between 25(OH)D and autism rating scales and between 25(OH)D and levels of an antineuronal antibody. This finding indicates that higher serum 25(OH)D concentrations may reduce the symptoms of established autism. Because activated vitamin D, a secosteroid, upregulates DNA-repair genes, vitamin D deficiency during development may inhibit the repair of de novo DNA mutations in fetuses and infants and thus contribute to risk of autism. Vitamin D might also reduce the risk or severity of autism through its anti-inflammatory actions, antiautoimmune effects, increasing seizure threshold, increasing T-regulatory cells, protecting the mitochondria, and upregulating glutathione, which scavenges oxidative by-products and chelates (captures and excretes) heavy metals. Vitamin D deficiency during pregnancy and childhood is a widespread and growing epidemic.

Keywords: Autism; DNA; antioxidants,; autoimmune disease; inflammation; seizures; vitamin D.

References

    1. Lu Z, Chen TC, Zhang A, Persons KS, Kohn N, Berkowitz R, et al. An evaluation of the vitamin D3 content in fish: Is the vitamin D content adequate to satisfy the dietary requirement for vitamin D? J Steroid Biochem Mol Biol. 2007;103:642–4. doi: 10.1016/j.jsbmb.2006.12.010.
    1. Cannell JJ, Hollis BW, Zasloff M, Heaney RP. Diagnosis and treatment of vitamin D deficiency. Expert Opin Pharmacother. 2008;9:107–18. doi: 10.1517/14656566.9.1.107.
    1. Eyles DW, Burne TH, McGrath JJ. Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol. 2013;34:47–64. doi: 10.1016/j.yfrne.2012.07.001.
    1. Cannell JJ. Autism and vitamin D. Med Hypotheses. 2008;70:750–9. doi: 10.1016/j.mehy.2007.08.016.
    1. Schnatz PF, Nudy M, O’Sullivan DM, Jiang X, Cline JM, Kaplan JR, et al. The quantification of vitamin D receptors in coronary arteries and their association with atherosclerosis. Maturitas. 2012;73:143–7. doi: 10.1016/j.maturitas.2012.03.014.
    1. Levin GP, Robinson-Cohen C, de Boer IH, Houston DK, Lohman K, Liu Y, et al. Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA. 2012;308:1898–905. doi: 10.1001/jama.2012.17304.
    1. Karohl C, Su S, Kumari M, Tangpricha V, Veledar E, Vaccarino V, et al. Heritability and seasonal variability of vitamin D concentrations in male twins. Am J Clin Nutr. 2010;92:1393–8. doi: 10.3945/ajcn.2010.30176.
    1. Kočovská E, Fernell E, Billstedt E, Minnis H, Gillberg C. Vitamin D and autism: clinical review. Res Dev Disabil. 2012;33:1541–50. doi: 10.1016/j.ridd.2012.02.015.
    1. Mostafa GA, Al-Ayadhi LY. Reduced serum concentrations of 25-hydroxy vitamin D in children with autism: relation to autoimmunity. J Neuroinflammation. 2012;9:201. doi: 10.1186/1742-2094-9-201.
    1. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet. 2010;376:180–8. doi: 10.1016/S0140-6736(10)60588-0.
    1. Meguid NA, Hashish AF, Anwar M, Sidhom G. Reduced serum levels of 25-hydroxy and 1,25-dihydroxy vitamin D in Egyptian children with autism. J Altern Complement Med. 2010;16:641–5. doi: 10.1089/acm.2009.0349.
    1. Xu B, Roos JL, Dexheimer P, Boone B, Plummer B, Levy S, et al. Exome sequencing supports a de novo mutational paradigm for schizophrenia. Nat Genet. 2011;43:864–8. doi: 10.1038/ng.902.
    1. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature. 2012;485:237–41. doi: 10.1038/nature10945.
    1. Julie G, Hamdan FF, Rouleau GA. A strategy to identify de novo mutations in common disorders such as autism and schizophrenia. J Vis Exp. 2011;52:2534.
    1. Veltman JA, Brunner HG. De novo mutations in human genetic disease. Nat Rev Genet. 2012;13:565–75. doi: 10.1038/nrg3241.
    1. Neale BM, Kou Y, Liu L, Ma’ayan A, Samocha KE, Sabo A, et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature. 2012;485:242–5. doi: 10.1038/nature11011.
    1. Grant WB, Cannell JJ. Autism prevalence in the United States with respect to solar ultraviolet-B doses: An ecological study. Dermatoendocrinol. 2013;5:9–14. doi: 10.4161/derm.22942.
    1. Fleet JC, DeSmet M, Johnson R, Li Y. Vitamin D and cancer: a review of molecular mechanisms. Biochem J. 2012;441:61–76. doi: 10.1042/BJ20110744.
    1. Haliska HD, Zhao H, Li J, Traganos F, Studzinski GP, Darzynkiewicz Z. Attenuation of constitutive DNA damage signaling by 1,25-dihydroxyvitamin D3. Aging (Albany, NY Online) 2012;4:270–8.
    1. Nair-Shalliker V, Armstrong BK, Fenech M. Does vitamin D protect against DNA damage? Mutat Res. 2012;733:50–7. doi: 10.1016/j.mrfmmm.2012.02.005.
    1. Ting HJ, Yasmin-Karim S, Yan SJ, Hsu JW, Lin TH, Zeng W, et al. A positive feedback signaling loop between ATM and the vitamin D receptor is critical for cancer chemoprevention by vitamin D. Cancer Res. 2012;72:958–68. doi: 10.1158/0008-5472.CAN-11-0042.
    1. Fedirko V, Bostick RM, Long Q, Flanders WD, McCullough ML, Sidelnikov E, et al. Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2010;19:280–91. doi: 10.1158/1055-9965.EPI-09-0448.
    1. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL. A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res. 1999;5:1339–45.
    1. Fedirko V, Bostick RM, Flanders WD, Long Q, Shaukat A, Rutherford RE, et al. Effects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double-blind, placebo-controlled clinical trial. Cancer Prev Res (Phila) 2009;2:213–23. doi: 10.1158/1940-6207.CAPR-08-0157.
    1. Chatterjee M. Vitamin D and genomic stability. Mutat Res. 2001;475:69–87. doi: 10.1016/S0027-5107(01)00080-X.
    1. Luxwolda MF, Kuipers RS, Kema IP, Dijck-Brouwer DA, Muskiet FA. Traditionally living populations in East Africa have a mean serum 25-hydroxyvitamin D concentration of 115 nmol/l. Br J Nutr. 2012;108:1557–61. doi: 10.1017/S0007114511007161.
    1. Malik M, Sheikh AM, Wen G, Spivack W, Brown WT, Li X. Expression of inflammatory cytokines, Bcl2 and cathepsin D are altered in lymphoblasts of autistic subjects. Immunobiology. 2011;216:80–5. doi: 10.1016/j.imbio.2010.03.001.
    1. Guillot X, Semerano L, Saidenberg-Kermanac’h N, Falgarone G, Boissier MC. Vitamin D and inflammation. Joint Bone Spine. 2010;77:552–7. doi: 10.1016/j.jbspin.2010.09.018.
    1. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. Curr Opin Pharmacol. 2010;10:482–96. doi: 10.1016/j.coph.2010.04.001.
    1. Cohly HH, Panja A. Immunological findings in autism. Int Rev Neurobiol. 2005;71:317–41. doi: 10.1016/S0074-7742(05)71013-8.
    1. Gao D, Trayhurn P, Bing C. 1,25-Dihydroxyvitamin D(3) inhibits the cytokine-induced secretion of MCP-1 and reduces monocyte recruitment by human preadipocytes. Int J Obes. 2012;37:356–65.
    1. Shedeed SA. Vitamin D supplementation in infants with chronic congestive heart failure. Pediatr Cardiol. 2012;33:713–9. doi: 10.1007/s00246-012-0199-6.
    1. Krishnan AV, Feldman D. Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Endocr Relat Cancer. 2010;17:R19–38. doi: 10.1677/ERC-09-0139.
    1. Tamiji J, Crawford DA. The neurobiology of lipid metabolism in autism spectrum disorders. Neurosignals. 2010;18:98–112. doi: 10.1159/000323189.
    1. Ziats MN, Rennert OM. Expression profiling of autism candidate genes during human brain development implicates central immune signaling pathways. PLoS One. 2011;6:e24691. doi: 10.1371/journal.pone.0024691.
    1. Fox E, Amaral D, Van de Water J. Maternal and fetal antibrain antibodies in development and disease. Dev Neurobiol. 2012;72:1327–34. doi: 10.1002/dneu.22052.
    1. Rout UK, Mungan NK, Dhossche DM. Presence of GAD65 autoantibodies in the serum of children with autism or ADHD. Eur Child Adolesc Psychiatry. 2012;21:141–7. doi: 10.1007/s00787-012-0245-1.
    1. Singh VK, Rivas WH. Prevalence of serum antibodies to caudate nucleus in autistic children. Neurosci Lett. 2004;355:53–6. doi: 10.1016/j.neulet.2003.10.026.
    1. Cabanlit M, Wills S, Goines P, Ashwood P, Van de Water J. Brain-specific autoantibodies in the plasma of subjects with autistic spectrum disorder. Ann N Y Acad Sci. 2007;1107:92–103. doi: 10.1196/annals.1381.010.
    1. Mostafa GA, Al-Ayadhi LY. Increased serum levels of anti-ganglioside M1 auto-antibodies in autistic children: relation to the disease severity. J Neuroinflammation. 2011;8:39. doi: 10.1186/1742-2094-8-39.
    1. Goines P, Haapanen L, Boyce R, Duncanson P, Braunschweig D, Delwiche L, et al. Autoantibodies to cerebellum in children with autism associate with behavior. Brain Behav Immun. 2011;25:514–23. doi: 10.1016/j.bbi.2010.11.017.
    1. Munoz LE, Schiller M, Zhao Y, Voll RE, Schett G, Herrmann M. Do low vitamin D levels cause problems of waste removal in patients with SLE? Rheumatology (Oxford) 2012;51:585–7. doi: 10.1093/rheumatology/ker334.
    1. Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. Cell Mol Biol (Noisy-le-grand) 2003;49:277–300.
    1. Lemire JM. Immunomodulatory role of 1,25-dihydroxyvitamin D3. J Cell Biochem. 1992;49:26–31. doi: 10.1002/jcb.240490106.
    1. Adorini L, Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol. 2008;4:404–12. doi: 10.1038/ncprheum0855.
    1. Mostafa GA, Al-Ayadhi LY. Reduced serum concentrations of 25-hydroxy vitamin D in children with autism: relation to autoimmunity. J Neuroinflammation. 2012;9:201. doi: 10.1186/1742-2094-9-201.
    1. Schwalfenberg GK. Solar radiation and vitamin D: mitigating environmental factors in autoimmune disease. J Environ Public Health. 2012;2012: 1. doi: 10.1155/2012/619381.
    1. Hara H. Autism and epilepsy: a retrospective follow-up study. Brain Dev. 2007;29:486–90. doi: 10.1016/j.braindev.2006.12.012.
    1. Siegel A, Malkowitz L, Moskovits MJ, Christakos S. Administration of 1,25-dihydroxyvitamin D3 results in the elevation of hippocampal seizure threshold levels in rats. Brain Res. 1984;298:125–9. doi: 10.1016/0006-8993(84)91153-3.
    1. Holló A, Clemens Z, Kamondi A, Lakatos P, Szücs A. Correction of vitamin D deficiency improves seizure control in epilepsy: a pilot study. Epilepsy Behav. 2012;24:131–3. doi: 10.1016/j.yebeh.2012.03.011.
    1. Dimeloe S, Nanzer A, Ryanna K, Hawrylowicz C. Regulatory T cells, inflammation and the allergic response-The role of glucocorticoids and Vitamin D. J Steroid Biochem Mol Biol. 2010;120:86–95. doi: 10.1016/j.jsbmb.2010.02.029.
    1. Toubi E, Shoenfeld Y. The role of vitamin D in regulating immune responses. Isr Med Assoc J. 2010;12:174–5.
    1. Pedersen AW, Claesson MH, Zocca MB. Dendritic cells modified by vitamin D: future immunotherapy for autoimmune diseases. Vitam Horm. 2011;86:63–82. doi: 10.1016/B978-0-12-386960-9.00003-4.
    1. Mostafa GA, Al Shehab A, Fouad NR. Frequency of CD4+CD25high regulatory T cells in the peripheral blood of Egyptian children with autism. J Child Neurol. 2010;25:328–35. doi: 10.1177/0883073809339393.
    1. Prietl B, Pilz S, Wolf M, Tomaschitz A, Obermayer-Pietsch B, Graninger W, et al. Vitamin D supplementation and regulatory T cells in apparently healthy subjects: vitamin D treatment for autoimmune diseases? Isr Med Assoc J. 2010;12:136–9.
    1. Neveu I, Naveilhan P, Jehan F, Baudet C, Wion D, De Luca HF, et al. 1,25-dihydroxyvitamin D3 regulates the synthesis of nerve growth factor in primary cultures of glial cells. Brain Res Mol Brain Res. 1994;24:70–6. doi: 10.1016/0169-328X(94)90119-8.
    1. Féron F, Burne TH, Brown J, Smith E, McGrath JJ, Mackay-Sim A, et al. Developmental Vitamin D3 deficiency alters the adult rat brain. Brain Res Bull. 2005;65:141–8. doi: 10.1016/j.brainresbull.2004.12.007.
    1. Frye RE, Rossignol DA. Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders. Pediatr Res. 2011;69:41R–7R. doi: 10.1203/PDR.0b013e318212f16b.
    1. García IM, Altamirano L, Mazzei LJ, Fornés MW, Molina MN, Ferder L, et al. Role of mitochondria in paricalcitol-mediated cytoprotection during obstructive nephropathy. Am J Physiol Renal Physiol. 2012;302:F1595–605. doi: 10.1152/ajprenal.00617.2011.
    1. Garcion E, Thanh XD, Bled F, Teissier E, Dehouck MP, Rigault F, et al. 1,25-Dihydroxyvitamin D3 regulates gamma 1 transpeptidase activity in rat brain. Neurosci Lett. 1996;216:183–6. doi: 10.1016/0304-3940(96)87802-5.
    1. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab. 2002;13:100–5. doi: 10.1016/S1043-2760(01)00547-1.
    1. Baas D, Prüfer K, Ittel ME, Kuchler-Bopp S, Labourdette G, Sarliève LL, et al. Rat oligodendrocytes express the vitamin D(3) receptor and respond to 1,25-dihydroxyvitamin D(3) Glia. 2000;31:59–68. doi: 10.1002/(SICI)1098-1136(200007)31:1<59::AID-GLIA60>;2-Y.
    1. Kern JK, Jones AM. Evidence of toxicity, oxidative stress, and neuronal insult in autism. J Toxicol Environ Health B Crit Rev. 2006;9:485–99. doi: 10.1080/10937400600882079.
    1. Chen KB, Lin AM, Chiu TH. Systemic vitamin D3 attenuated oxidative injuries in the locus coeruleus of rat brain. Ann N Y Acad Sci. 2003;993:313–24, discussion 345-9. doi: 10.1111/j.1749-6632.2003.tb07539.x.
    1. Lin AM, Chen KB, Chao PL. Antioxidative effect of vitamin D3 on zinc-induced oxidative stress in CNS. Ann N Y Acad Sci. 2005;1053:319–29. doi: 10.1196/annals.1344.028.
    1. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem. 2005;12:1161–208. doi: 10.2174/0929867053764635.
    1. Halicka HD, Zhao H, Li J, Traganos F, Studzinski GP, Darzynkiewicz Z. Attenuation of constitutive DNA damage signaling by 1,25-dihydroxyvitamin D3. Aging (Albany NY) 2012;4:270–8.
    1. Mitri J, Dawson-Hughes B, Hu FB, Pittas AG. Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. Am J Clin Nutr. 2011;94:486–94. doi: 10.3945/ajcn.111.011684.
    1. Kelly A, Brooks LJ, Dougherty S, Carlow DC, Zemel BS. A cross-sectional study of vitamin D and insulin resistance in children. Arch Dis Child. 2011;96:447–52. doi: 10.1136/adc.2010.187591.
    1. Fujita-Shimizu A, Suzuki K, Nakamura K, Miyachi T, Matsuzaki H, Kajizuka M, et al. Decreased serum levels of adiponectin in subjects with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:455–8. doi: 10.1016/j.pnpbp.2009.12.020.
    1. Vaidya A, Williams JS, Forman JP. The independent association between 25-hydroxyvitamin D and adiponectin and its relation with BMI in two large cohorts: the NHS and the HPFS. Obesity (Silver Spring) 2012;20:186–91. doi: 10.1038/oby.2011.210.
    1. (accessed 3/2/2013)

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren